Drug Trial Radar · NCT05234437
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
Last checked: Nov 20, 2026Latest source record: Apr 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Mar 9, 2022
Primary completion
Jul 18, 2022
Study completion Jul 18, 2022
Sponsor
- Lead sponsor
- QBiotics Group LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma
Conditions
- Melanoma
Interventions
tigilanol tiglateDrug
Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2. Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumour ResponsesTime frame: 36 months
- Tumour AblationTime frame: 36 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Cairns and Hinterland Hospital and Health Service
Cairns, Queensland, Australia
Metro South Hospital and Health Service via Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.